Thalassemia and hepatocellular carcinoma: links and risks

References

• Vitrano A, Calvaruso G, Lai E, et al. The era of comparable life expectancy between thalassaemia major and intermedia: is it time to revisit the major-intermedia dichotomy? Br J Haematol. 2017;176(1):124–130. doi:10.1111/bjh.1438127748513
   PubMed Web of Science ®Google Scholar
• Taher AT, Mussalam K, Cappellini MD. Guidelines for the Management of Non Transfusion Dependent Editors of the 2nd Edition. TIF; 2018.
   Google Scholar
• Ricchi P, Ammirabile M, Costantini S, et al. Splenectomy is a risk factor for developing hyperuricemia and nephrolithiasis in patients with thalassemia intermedia: a retrospective study. Blood Cells Mol Dis. 2012;49(3–4):133–135. doi:10.1016/j.bcmd.2012.05.01222705193
   PubMed Web of Science ®Google Scholar
• Ricchi P, Ammirabile M, Costantini S, et al. A useful relationship between the presence of extramedullary erythropoeisis and the level of the soluble form of the transferrin receptor in a large cohort of adult patients with thalassemia intermedia: a prospective study. Ann Hematol. 2012;91(6):905–909. doi:10.1007/s00277-011-1385-y22167341
   PubMed Web of Science ®Google Scholar
• Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008;10(1):1–8. doi:10.1186/1532-429X-10-42
   Web of Science ®Google Scholar
• Ricchi P, Ammirabile M, Spasiano A, et al. Combined chelation therapy in thalassemia major with deferiprone and desferrioxamine: a retrospective study. Eur J Haematol. 2010;85(1):36–42.20331740
   PubMed Web of Science ®Google Scholar
• Pepe A, Meloni A, Rossi G, et al. Cardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapy. J Cardiovasc Magn Reson. 2013;15(1):1–11. doi:10.1186/1532-429X-15-123324167
   PubMed Web of Science ®Google Scholar
• Dessi C, Leoni G, Moi P, et al. Thalassemia major between liver and heart: where we are now. Blood Cells Mol Dis. 2015;55(1):82–88.25976473
   PubMed Web of Science ®Google Scholar
• Aydinok Y, Porter JB, Piga A, et al. Prevalence and distribution of iron overload in patients with transfusion-dependent anemias differs across geographic regions: results from the CORDELIA study. Eur J Haematol. 2015;95(3):244–253.25418187
   PubMed Web of Science ®Google Scholar
• Petrick JL, Kelly SP, Altekruse SF, McGlynn KA, Rosenberg PS. Future of hepatocellular carcinoma incidence in the United States forecast through 2030. J Clin Oncol. 2016;34(15):1787–1794. doi:10.1200/JCO.2015.64.741227044939
   PubMed Web of Science ®Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386. doi:10.1002/ijc.2921025220842
   PubMed Web of Science ®Google Scholar
• Globocan. Liver fact sheet. Available from: http://gco.iarc.fr/today/data/factsheets/cancers/11-Liver-fact-sheet.pdf. Accessed 8, 22 2019.
   Google Scholar
• Borgna-Pignatti C, De Stefano P, Sessa F, Avato F. Hepatocellular carcinoma in thalassemia major. Med Pediatr Oncol. 1986;14(6):327–328.2431257
   PubMedGoogle Scholar
• Moukhadder HM, Halawi R, Cappellini MD, Taher AT. Hepatocellular carcinoma as an emerging morbidity in the thalassemia syndromes: a comprehensive review. Cancer. 2017;123(5):751–758. doi:10.1002/cncr.3046227911488
   PubMed Web of Science ®Google Scholar
• Finianos A, Matar CF, Taher A. Hepatocellular carcinoma in β-thalassemia patients : review of the literature with molecular insight into liver carcinogenesis. Int J Mol Sci. 2018;19(12):4070. doi:10.3390/ijms19124070.
   Web of Science ®Google Scholar
• Zurlo MG, De Stefano P, Borgna-Pignatti C, et al. Survival and causes of death in thalassaemia major. Lancet (London, England). 1989;2(8653):27–30. doi:10.1016/s0140-6736(89)90264-x
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Garani MC, Forni GL, et al. Hepatocellular carcinoma in thalassaemia: an update of the Italian registry. Br J Haematol. 2014;167(1):121–126. doi:10.1111/bjh.1300924992281
   PubMed Web of Science ®Google Scholar
• Ansari S, Azarkivan A, Halagi F. Incidence of hepatocellular carcinoma in patients with thalassemia who had hepatitis C. Acta Med Iran. 2013;51(6):404–407.23852846
   PubMedGoogle Scholar
• Borgna-Pignatti C, Vergine G, Lombardo T, et al. Hepatocellular carcinoma in the thalassaemia syndromes. Br J Haematol. 2004;124(1):114–117. doi:10.1046/j.1365-2141.2003.04732.x14675416
   PubMed Web of Science ®Google Scholar
• Fragatou S, Tsourveloudis I, Manesis G. Incidence of hepatocellular carcinoma in a thalassemia unit. Hemoglobin. 2010;34(3):221–226. doi:10.3109/03630269.2010.48507120524812
   PubMed Web of Science ®Google Scholar
• Maakaron JE, Cappellini MD, Graziadei G, Ayache JB, Taher AT. Hepatocellular Carcinoma in Hepatitis-Negative Patients with Thalassemia Intermedia: A Closer Look at the Ann Hepatol. 2013;12(1):142–146.
   Google Scholar
• Maakaron JE, Musallam KM, Ayache JB, Jabbour M, Tawil AN, Taher AT. A liver mass in an iron-overloaded thalassaemia intermedia patient. Br J Haematol. 2013;161(1):1. doi:10.1111/bjh.12195
   PubMed Web of Science ®Google Scholar
• Mancuso A, Rigano P, Renda D, et al. Hepatocellular carcinoma on cirrhosis-free liver in a HCV-infected thalassemic. Am J Hematol. 2005;78(2):158–159. doi:10.1002/ajh.20289
   PubMed Web of Science ®Google Scholar
• Mancuso A, Sciarrino E, Renda MC, Maggio A. A prospective study of hepatocellular carcinoma incidence in thalassemia. Hemoglobin. 2006;30(1):119–124. doi:10.1080/0363026050045556516540424
   PubMed Web of Science ®Google Scholar
• Moukhadder HM, Roumi JE, Bou-Fakhredin R, Taher AT. Hepatocellular carcinoma in a beta-thalassemia intermedia patient: yet another case in the expanding epidemic. Hemoglobin. 2018;42(1):58–60. doi:10.1080/03630269.2018.143419729493312
   PubMed Web of Science ®Google Scholar
• Restivo PG, Renda D, Valenza F, et al. Hepatocellular carcinoma in patients with thalassaemia syndromes: clinical characteristics and outcome in a long term single centre experience. Br J Haematol. 2010;150:226–248. doi:10.1111/j.1365-2141.2010.08179.x20433679
   PubMed Web of Science ®Google Scholar
• Musallam KM, Cappellini MD, Wood JC, Taher AT. Iron overload in non-transfusion-dependent thalassemia: a clinical perspective. Blood Rev. 2012;26(Suppl 1):S16–S19. doi:10.1016/S0268-960X(12)70006-122631036
   PubMed Web of Science ®Google Scholar
• Globocan. Estimated age-standardized incidence and mortality rates for liver cancer (Southern Europe) in 2018, all ages. Available from: http://gco.iarc.fr/today/online-analysis-dual-bars-2. Published 2018 Accessed 8, 22 2019.
   Google Scholar
• Leong TY-M, Leong AS-Y. Epidemiology and carcinogenesis of hepatocellular carcinoma. HPB (Oxford). 2005;7(1):5–15. doi:10.1080/1365182041002402118333156
   PubMedGoogle Scholar
• Mahmoudvand S, Shokri S, Taherkhani R, Farshadpour F. Hepatitis c virus core protein modulates several signaling pathways involved in hepatocellular carcinoma. World J Gastroenterol. 2019;25(1):42–58. doi:10.3748/wjg.v25.i1.4230643357
   PubMed Web of Science ®Google Scholar
• Wonke B, Hoffbrand AV, Brown D, Dusheiko G. Antibody to hepatitis C virus in multiply transfused patients with thalassaemia major. J Clin Pathol. 1990;43(8):638–640. doi:10.1136/jcp.43.8.6382119395
   PubMed Web of Science ®Google Scholar
• Origa R, Ponti ML, Filosa A, et al. Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies. Am J Hematol. 2017;92(12):1349–1355. doi:10.1002/ajh.2491128929515
   PubMed Web of Science ®Google Scholar
• Mancuso A. Hepatocellular carcinoma in thalassemia: a critical review. World J Hepatol. 2010;2(5):171–174. doi:10.4254/wjh.v2.i5.17121160991
   PubMedGoogle Scholar
• Schulze-Krebs A, Preimel D, Popov Y, et al. Hepatitis C virus-replicating hepatocytes induce fibrogenic activation of hepatic stellate cells. Gastroenterology. 2005;129(1):246–258. doi:10.1053/j.gastro.2005.03.08916012951
   PubMed Web of Science ®Google Scholar
• Angelucci E, Muretto P, Nicolucci A, et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood. 2002;100(1):17–21. doi:10.1182/blood.v100.1.1712070002
   PubMed Web of Science ®Google Scholar
• Zou DM, Sun WL. Relationship between hepatitis C virus infection and iron overload. Chin Med J (Engl). 2017;130(7):866–871. doi:10.4103/0366-6999.20273728345552
   PubMed Web of Science ®Google Scholar
• Girelli D, Pasino M, Goodnough JB, et al. Reduced serum hepcidin levels in patients with chronic hepatitis C. J Hepatol. 2009;51(5):845–852. doi:10.1016/j.jhep.2009.06.02719729219
   PubMed Web of Science ®Google Scholar
• Kato J, Miyanishi K, Kobune M, et al. Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. J Gastroenterol. 2007;42(10):830–836. doi:10.1007/s00535-007-2095-z17940836
   PubMed Web of Science ®Google Scholar
• Kanda T, Goto T, Hirotsu Y, Moriyama M, Omata M. Molecular mechanisms driving progression of liver cirrhosis towards hepatocellular carcinoma in chronic hepatitis B and C infections: a review. Int J Mol Sci. 2019;20(6):1358. doi:10.3390/ijms20061358
   PubMed Web of Science ®Google Scholar
• Szmuness W. Hepatocellular carcinoma and the hepatitis B virus: evidence for a causal association. Prog Med Virol. 1978;24:40–69.212785
   PubMedGoogle Scholar
• Petruzziello A. Epidemiology of hepatitis B virus (HBV) and hepatitis C virus (HCV) related hepatocellular carcinoma. Open Virol J. 2018;12(1):26–32. doi:10.2174/187435790181201002629541276
   PubMedGoogle Scholar
• Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology. 1995;21(3):650–655.7875662
   PubMed Web of Science ®Google Scholar
• Tawada A, Kanda T, Imazeki F, Yokosuka O. Prevention of hepatitis B virus-associated liver diseases by antiviral therapy. Hepatol Int. 2016;10(4):574–593. doi:10.1007/s12072-016-9720-y27026375
   PubMed Web of Science ®Google Scholar
• Kanda T, Wu S, Sasaki R, et al. HBV core protein enhances cytokine production. Dis (Basel, Switzerland). 2015;3(3):213–220.
   Google Scholar
• Raimondo G, Navarra G, Mondello S, et al. Occult hepatitis B virus in liver tissue of individuals without hepatic disease. J Hepatol. 2008;48(5):743–746. doi:10.1016/j.jhep.2008.01.02318314221
   PubMed Web of Science ®Google Scholar
• Siagris D, Christofidou M, Triga K, et al. Occult hepatitis B virus infection in hemodialysis patients with chronic HCV infection. J Nephrol. 2006;19(3):327–333.16874693
   PubMed Web of Science ®Google Scholar
• Hollinger FB. Hepatitis B virus infection and transfusion medicine: science and the occult. Transfusion. 2008;48(5):1001–1026. doi:10.1111/j.1537-2995.2008.01701.x18454738
   PubMed Web of Science ®Google Scholar
• Spreafico M, Berzuini A, Foglieni B, et al. Poor efficacy of nucleic acid testing in identifying occult HBV infection and consequences for safety of blood supply in Italy. J Hepatol. 2015;63(5):1068–1076. doi:10.1016/j.jhep.2015.06.01626116791
   PubMed Web of Science ®Google Scholar
• Mortensen E, Kamali A, Schirmer PL, et al. Are current screening protocols for chronic hepatitis B virus infection adequate? Diagn Microbiol Infect Dis. 2016;85(2):159–167. doi:10.1016/j.diagmicrobio.2015.12.00527009896
   PubMed Web of Science ®Google Scholar
• Cholongitas E, Haidich A-B, Apostolidou-Kiouti F, Chalevas P, Papatheodoridis GV. Hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy: a systematic review. Ann Gastroenterol. 2018;31(4):480–490. doi:10.20524/aog.2018.026629991894
   PubMed Web of Science ®Google Scholar
• Di Stefano M, Volpe A, Stallone G, et al. Occult HBV infection in hemodialysis setting is marked by presence of isolated antibodies to HBcAg and HCV. J Nephrol. 2009;22(3):381–386.19557715
   PubMed Web of Science ®Google Scholar
• Hassan ZK, Hafez MM, Mansor TM, Zekri ARN. Occult HBV infection among Egyptian hepatocellular carcinoma patients. Virol J. 2011;8:90. doi:10.1186/1743-422X-8-9021371325
   PubMed Web of Science ®Google Scholar
• Liu C-J, Chen D-S, Chen P-J. Epidemiology of HBV infection in Asian blood donors: emphasis on occult HBV infection and the role of NAT. J Clin Virol. 2006;36(Suppl 1):S33–S44.16831692
   PubMed Web of Science ®Google Scholar
• Candotti D, Grabarczyk P, Ghiazza P, et al. Characterization of occult hepatitis B virus from blood donors carrying genotype A2 or genotype D strains. J Hepatol. 2008;49(4):537–547. doi:10.1016/j.jhep.2008.04.01718602718
   PubMed Web of Science ®Google Scholar
• Raimondo G, Locarnini S, Pollicino T, Levrero M, Zoulim F, Lok AS. Update of the statements on biology and clinical impact of occult hepatitis b virus infection. J Hepatol. 2019. doi:10.1016/j.jhep.2019.03.034
   Web of Science ®Google Scholar
• Mandishona E, MacPhail AP, Gordeuk VR, et al. Dietary iron overload as a risk factor for hepatocellular carcinoma in Black Africans. Hepatology. 1998;27(6):1563–1566. doi:10.1002/hep.5102706149620327
   PubMed Web of Science ®Google Scholar
• Kowdley KV. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology. 2004;127(5 Suppl 1):S79–S86. doi:10.1016/j.gastro.2004.09.01915508107
   PubMed Web of Science ®Google Scholar
• Blanc JF, De Ledinghen V, Bernard PH, et al. Increased incidence of HFE C282Y mutations in patients with iron overload and hepatocellular carcinoma developed in non-cirrhotic liver. J Hepatol. 2000;32(5):805–811.10845668
   PubMed Web of Science ®Google Scholar
• Bralet MP, Regimbeau JM, Pineau P, et al. Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 French cases. Hepatology. 2000;32(2):200–204. doi:10.1053/jhep.2000.903310915724
   PubMed Web of Science ®Google Scholar
• Herrinton LJ, Friedman GD, Baer D, Selby JV. Transferrin saturation and risk of cancer. Am J Epidemiol. 1995;142(7):692–698.7572938
   PubMed Web of Science ®Google Scholar
• Ioannou GN, Kowdley KV. Iron, HFE mutations, and hepatocellular carcinoma: is hepatic iron a carcinogen? Clin Gastroenterol Hepatol. 2003;1(4):246–248. doi:10.1016/S1542-3565(03)00126-515017663
   PubMed Web of Science ®Google Scholar
• Moyo VM, Makunike R, Gangaidzo IT, et al. African iron overload and hepatocellular carcinoma (HA-7-0-080). Eur J Haematol. 1998;60(1):28–34.9451425
   PubMed Web of Science ®Google Scholar
• Turlin B, Juguet F, Moirand R, et al. Increased liver iron stores in patients with hepatocellular carcinoma developed on a noncirrhotic liver. Hepatology. 1995;22(2):446–450.7635411
   PubMed Web of Science ®Google Scholar
• Taher A, Hershko C, Cappellini MD. Iron overload in thalassaemia intermedia: reassessment of iron chelation strategies. Br J Haematol. 2009;147(5):634–640. doi:10.1111/j.1365-2141.2009.07848.x19681884
   PubMed Web of Science ®Google Scholar
• Nemeth E. Hepcidin in beta-thalassemia. Ann N Y Acad Sci. 2010;1202:31–35. doi:10.1111/j.1749-6632.2010.05585.x20712769
   PubMed Web of Science ®Google Scholar
• Matzner Y, Hershko C, Polliack A, Konijn AM, Izak G. Suppressive effect of ferritin on in vitro lymphocyte function. Br J Haematol. 1979;42(3):345–353. doi:10.1111/j.1365-2141.1979.tb01142.x157770
   PubMed Web of Science ®Google Scholar
• Walker EMJ, Walker SM. Effects of iron overload on the immune system. Ann Clin Lab Sci. 2000;30(4):354–365.11045759
   PubMed Web of Science ®Google Scholar
• Green R, Esparza I, Schreiber R. Iron inhibits the nonspecific tumoricidal activity of macrophages. A possible contributory mechanism for neoplasia in hemochromatosis. Ann N Y Acad Sci. 1988;526:301–309. doi:10.1111/j.1749-6632.1988.tb55514.x2455463
   PubMed Web of Science ®Google Scholar
• Djeha A, Brock JH. Effect of transferrin, lactoferrin and chelated iron on human T-lymphocytes. Br J Haematol. 1992;80(2):235–241. doi:10.1111/j.1365-2141.1992.tb08906.x1550782
   PubMed Web of Science ®Google Scholar
• Deugnier Y, Turlin B. Iron and hepatocellular carcinoma. J Gastroenterol Hepatol. 2001;16(5):491–494.11350542
   PubMed Web of Science ®Google Scholar
• Seligman PA, Kovar J, Gelfand EW. Lymphocyte proliferation is controlled by both iron availability and regulation of iron uptake pathways. Pathobiology. 1992;60(1):19–26. doi:10.1159/0001636921543546
   PubMed Web of Science ®Google Scholar
• Taher AT, Porter JB, Viprakasit V, et al. Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia. Br J Haematol. 2015;168(2):284–290.25212456
   PubMed Web of Science ®Google Scholar
• Ricchi P, Meloni A, Spasiano A, et al. The impact of liver steatosis on the ability of serum ferritin levels to be predictive of liver iron concentration in non-transfusion-dependent thalassaemia patients. Br J Haematol. 2018;180(5):721–726.29363758
   PubMed Web of Science ®Google Scholar
• Clouston AD, Powell EE. Interaction of non-alcoholic fatty liver disease with other liver diseases. Best Pract Res Clin Gastroenterol. 2002;16(5):767–781.12406444
   PubMed Web of Science ®Google Scholar
• Paradis V, Zalinski S, Chelbi E, et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology. 2009;49(3):851–859.19115377
   PubMed Web of Science ®Google Scholar
• Divella R, Mazzocca A, Daniele A, Sabba C, Obesity PA. Nonalcoholic fatty liver disease and adipocytokines network in promotion of cancer. Int J Biol Sci. 2019;15(3):610–616.30745847
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Otgonsuren M, Henry L, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology. 2015;62(6):1723–1730.26274335
   PubMed Web of Science ®Google Scholar
• Puoti C. New insights on hepatocellular carcinoma: epidemiology and clinical aspects. Hepatoma Res. 2018;4(9):57.
   Google Scholar
• Lin H, Fu C, Kannengiesser S, et al. Quantitative analysis of hepatic iron in patients suspected of coexisting iron overload and steatosis using multi-echo single-voxel magnetic resonance spectroscopy: Comparison with fat-saturated multi-echo gradient echo sequence. J Magn Reson Imaging. 2018;48(1):205–213. doi:10.1002/jmri.2596729513377
   PubMed Web of Science ®Google Scholar
• Gamberini MR, De Sanctis V, Gilli G. Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre. Pediatr Endocrinol Rev. 2008;6(Suppl 1):158–169.19337172
   PubMedGoogle Scholar
• Multicentre study on prevalence of endocrine complications in thalassaemia major. Italian working group on endocrine complications in non-endocrine diseases. Clin Endocrinol (Oxf). 1995;42(6):581–586.7634497
   PubMed Web of Science ®Google Scholar
• De Sanctis V, Roos M, Gasser T, Fortini M, Raiola G, Galati MC. Impact of long-term iron chelation therapy on growth and endocrine functions in thalassaemia. J Pediatr Endocrinol Metab. 2006;19(4):471–480.16759032
   PubMed Web of Science ®Google Scholar
• Mancuso A, Perricone G. Time to define a new strategy for management of hepatocellular carcinoma in thalassaemia? Br J Haematol. 2015;168(2):304–305.25146379
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Gamberini MR. Complications of thalassemia major and their treatment. Expert Rev Hematol. 2011;4(3):353–366.21668399
   PubMed Web of Science ®Google Scholar
• Koh W-P, Wang R, Jin A, Yu MC, J-M Y. Diabetes mellitus and risk of hepatocellular carcinoma: findings from the Singapore Chinese health study. Br J Cancer. 2013;108(5):1182–1188.23370206
   PubMed Web of Science ®Google Scholar
• Mantovani A, Targher G. Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease. Ann Transl Med. 2017;5(13):270.28758096
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208–1236.16250051
   PubMed Web of Science ®Google Scholar
• Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362(9399):1907–1917.14667750
   PubMed Web of Science ®Google Scholar
• Rampone B, Schiavone B, Martino A, Viviano C, Confuorto G. Current management strategy of hepatocellular carcinoma. World J Gastroenterol. 2009;15(26):3210–3216.19598295
   PubMed Web of Science ®Google Scholar
• Poon D, Anderson BO, Chen L-T, et al. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 2009;10(11):1111–1118.19880065
   PubMed Web of Science ®Google Scholar
• Verslype C, Van Cutsem E, Dicato M, et al. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th world congress on gastrointestinal cancer, Barcelona, 2008. Ann Oncol Off J Eur Soc Med Oncol. 2009;20(Suppl 7):vii1–vii6.
   Google Scholar
• El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134(6):1752–1763.18471552
   PubMed Web of Science ®Google Scholar
• Tanwar S, Khan SA, Grover VPB, Gwilt C, Smith B, Brown A. Liver transplantation for hepatocellular carcinoma. World J Gastroenterol. 2009;15(44):5511–5516.19938188
   PubMed Web of Science ®Google Scholar
• Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol. 2008;48(Suppl 1):S20–S37.18304676
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the study of the liver. J Hepatol. 2001;35(3):421–430.11592607
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ducreux M, Lencioni R, et al. EASL-EORTC Clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer. 2012;48(5):599–641.22424278
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Liu PP, Sher GD, et al. Brief report: combined liver and heart transplantation for end-stage iron-induced organ failure in an adult with homozygous beta-thalassemia. N Engl J Med. 1994;330(16):1125–1127.8133854
   PubMed Web of Science ®Google Scholar
• Mela M, Mancuso A, Burroughs AK. Review article: hepatocellular carcinoma: indications for liver transplantation. Aliment Pharmacol Ther. 2003;17(Suppl 2):130–137.12786624
   PubMed Web of Science ®Google Scholar
• Menon KV, Hakeem AR, Heaton ND. Review article: liver transplantation for hepatocellular carcinoma - a critical appraisal of the current worldwide listing criteria. Aliment Pharmacol Ther. 2014;40(8):893–902.25155143
   PubMed Web of Science ®Google Scholar
• Ricchi P, Meloni A, Di Matola T, et al. Galectin-3 and myocardial fibrosis by cardiac magnetic resonance in thalassaemia major. Blood. 2016;128(22):4832LP- 4832.
   Web of Science ®Google Scholar
• Trinchet JC, Chaffaut C, Bourcier V, et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology. 2011;54(6):1987–1997. doi:10.1002/hep.2454522144108
   PubMed Web of Science ®Google Scholar
• Tzartzeva K, Obi J, Rich NE, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology. 2018;154(6):1706–1718.e1. doi:10.1053/j.gastro.2018.01.06429425931
   PubMed Web of Science ®Google Scholar
• Musallam KM, Cappellini MD, Wood JC, et al. Elevated liver iron concentration is a marker of increased morbidity in patients with beta thalassemia intermedia. Haematologica. 2011;96(11):1605–1612. doi:10.3324/haematol.2011.04785221791471
   PubMed Web of Science ®Google Scholar
• Berdoukas V, Farmaki K, Wood JC, Coates T. Iron chelation in thalassemia: time to reconsider our comfort zones. Expert Rev Hematol. 2011;4(1):17–26. doi:10.1586/ehm.10.7421322775
   PubMed Web of Science ®Google Scholar
• Fibach E, Rachmilewitz EA. The role of antioxidants and iron chelators in the treatment of oxidative stress in thalassemia. Ann N Y Acad Sci. 2010;1202:10–16. doi:10.1111/j.1749-6632.2010.05577.x20712766
   PubMed Web of Science ®Google Scholar
• Di Marco V, Capra M, Angelucci E, et al. Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. Blood. 2010;116(16):2875–2883. doi:10.1182/blood-2009-11-24872420551378
   PubMed Web of Science ®Google Scholar
• Di Marco V, Capra M, Gagliardotto F, et al. Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C. Haematologica. 2008;93(8):1243–1246. doi:10.3324/haematol.1255418556410
   PubMed Web of Science ®Google Scholar
• Hershko C. Pathogenesis and management of iron toxicity in thalassemia. Ann N Y Acad Sci. 2010;1202:1–9. doi:10.1111/j.1749-6632.2010.05544.x20712765
   PubMed Web of Science ®Google Scholar
• EASL. Recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66(1):153–194. doi:10.1016/j.jhep.2016.09.001.27667367
   PubMed Web of Science ®Google Scholar
• Harmatz P, Jonas MM, Kwiatkowski JL, et al. Safety and efficacy of pegylated interferon alpha-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia. Haematologica. 2008;93(8):1247–1251. doi:10.3324/haematol.1235218556414
   PubMed Web of Science ®Google Scholar
• Inati A, Taher A, Ghorra S, et al. Efficacy and tolerability of peginterferon alpha-2a with or without ribavirin in thalassaemia major patients with chronic hepatitis C virus infection. Br J Haematol. 2005;130(4):644–646. doi:10.1111/j.1365-2141.2005.05645.x16098081
   PubMed Web of Science ®Google Scholar
• Di Marco V, D’Ambrosio R, Bronte F, et al. Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: is there still an indication? Dig Liver Dis. 2016;48(6):650–655. doi:10.1016/j.dld.2016.02.00427012446
   PubMedGoogle Scholar
• Kamal SM, Fouly AH, Mohamed MK, et al. Peginterferon alpha-2b therapy with and without ribavirin in patients with thalassemia: a randomized study. J Hepatol. 2006;44:S217. doi:10.1016/j.jhep.2005.09.019
   PubMed Web of Science ®Google Scholar
• Ricchi P, Ammirabile M, Costantini S, et al. The impact of previous or concomitant IFN therapy on deferiprone-induced agranulocytosis and neutropenia: a retrospective study. Expert Opin Drug Saf. 2010;9(6):875–881. doi:10.1517/14740338.2010.51083120945995
   PubMed Web of Science ®Google Scholar
• Ricchi P, Lanza AG, Ammirabile M, et al. Hepatitis C virus distribution and clearance following interferon-monotherapy among thalassaemia major and intermedia patients. Br J Haematol. 2011;155(4):524–527. doi:10.1111/j.1365-2141.2011.08717.x21564076
   PubMed Web of Science ®Google Scholar
• Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879–1888. doi:10.1056/NEJMoa140235524720702
   PubMed Web of Science ®Google Scholar
• Prati D, Maggioni M, Milani S, et al. Clinical and histological characterization of liver disease in patients with transfusion-dependent beta-thalassemia. A multicenter study of 117 cases. Haematologica. 2004;89(10):1179–1186.15477201
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Jacobson IM, Nelson DR. Daclatasvir plus sofosbuvir for HCV infection. N Engl J Med. 2014;370(16):1560–1561. doi:10.1056/NEJMc1401726
   PubMed Web of Science ®Google Scholar
• Sharara AI, Rustom LBO, Marrache M, et al. Sofosbuvir/velpatasvir for chronic hepatitis C infection in patients with transfusion-dependent thalassemia. Am J Hematol. 2019;94(2):E43–E45. doi:10.1002/ajh.2533930394575
   PubMed Web of Science ®Google Scholar
• Ponti ML, Comitini F, Murgia D, et al. Impact of the direct-acting antiviral agents (DAAs) on chronic hepatitis C in Sardinian patients with transfusion-dependent Thalassemia major. Dig Liver Dis. 2019;51(4):561–567. doi:10.1016/j.dld.2018.12.01630658940
   PubMedGoogle Scholar
• Aleman S, Rahbin N, Weiland O, et al. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis. 2013;57(2):230–236.23616492
   PubMed Web of Science ®Google Scholar
• van der Meer AJ, Feld JJ, Hofer H, et al. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. J Hepatol. 2017;66(3):485–493. doi:10.1016/j.jhep.2016.10.01727780714
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Kanwal F, Richardson P, Kramer J. Risk of hepatocellular carcinoma after sustained virological response in veterans with hepatitis C virus infection. Hepatology. 2016;64(1):130–137. doi:10.1002/hep.2853526946190
   PubMed Web of Science ®Google Scholar
• Makiyama A, Itoh Y, Kasahara A, et al. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer. 2004;101(7):1616–1622. doi:10.1002/cncr.2053715378504
   PubMed Web of Science ®Google Scholar
• Su F, Ioannou GN. Hepatocellular carcinoma risk after direct‐acting antiviral therapy. Clin Liver Dis. 2019;13(1):6–12. doi:10.1002/cld.781
   Google Scholar
• Li H, Huang M-H, Jiang J-D, Peng Z-G, Hepatitis C. From inflammatory pathogenesis to anti-inflammatory/hepatoprotective therapy. World J Gastroenterol. 2018;24(47):5297–5311. doi:10.3748/wjg.v24.i47.529730598575
   PubMed Web of Science ®Google Scholar